Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.

Abstract excerpt

Precision medicine in non-small cell lung cancer (NSCLC) is a rapidly evolving area, with the development of targeted therapies for advanced disease and concomitant molecular testing to inform clinical decision-making. In contrast, routine molecular testing in stage I-III disease has not been required, where standard of care comprises surgery with or without adjuvant or neoadjuvant chemotherapy, or concurrent...

Topics

Join the communities discussing this publication.

• Carcinoma, Non-Small-Cell Lung
• ErbB Receptors
• Lung Neoplasms
• Molecular Diagnostic Techniques
• Mutation